BIOPHYTIS (EPA:ALBPS) - Biophytis Reinforces Leadership Teams with Three Senior Appointments

Transparency directive : regulatory news

08/07/2021 08:00

Press release

Biophytis Reinforces Leadership Teams with Three Senior Appointments

* Claude Allary to be member of Board of Directors
* Benoit Canolle is appointed Chief Business Officer
* Jean Mariani, Chairman of Biophytis Scientific Committee to take over the
Chief Medical Officer role

Paris, France, Cambridge (Massachusetts, United States), July 8, 2021, 8:00 am.
CEST - Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS),
("Biophytis" or the "company"), - Biophytis SA (NasdaqCM: BPTS, Euronext Growth
Paris: ALBPS), a clinical-stage biotechnology company focused on the
development of therapeutics that are aimed at slowing the degenerative
processes associated with aging and improving functional outcomes for patients
suffering from age-related diseases, including severe respiratory failure in
patients suffering from COVID-19 today announces the strengthening of its
leadership teams with three new appointments of highly experienced healthcare
executives.

Claude Allary will become a member of the Board of Directors, replacing Jean
Franchi, following the approval by Biophytis Board of Directors held on July 7,
2021.
Benoit canolle is named Chief Business Officer, and will be member of the
Executive Committee.
Jean Mariani, Chairman of the Biophytis Scientific Committee will replace Sam
Agus as Chief Medical Officer, during a transition period before the appointed
new CMO joins the Company.

Claude Allary has been working with Healthcare Industries for the past 40
years. Starting with the Pharmaceuticals Industry (Sanofi, Pfizer, GSK), he
then moved to Arthur D. Little where he trained into management consulting and
continued with Deloitte. In 2002, he co-founded Bionest Partners, of which he
is now a Senior Advisor.
He added Executive Coaching and, lately, directorships to provide well-rounded
support to companies. He devotes an important part of his time to Patients'
Associations. He recently co- founded new service companies: Humanim (Life
Sciences Manufacturing) and Les Mauvais Elèves (Think Tank on work changes in
companies).
Claude graduated from ESSEC and holds a Ph.D. in Management Sciences. He has
been a Financial Analyst from 2005 to 2011.

With a PhD degree in Neuroscience, Benoit Canolle joins from Pierre Fabre Group
& Sanofi & Galderma. At Pierre Fabre, he was Head of Corporate Medical
Portfolio & Project Direction. At Sanofi, he held several Project Director's
roles mostly for the Immuno-Inflammation development franchise. He has 16
years' experience in pharma R&D, with substantial medical and scientific
expertise in neurology, immunology and rare diseases. He has a strong track
record of successfully managing business and academic collaborations.

Director of the Institut de la Longévité Charles Foix [Longevity Institute],
geriatrician and a practitioner at the hospital, director of the CNRS-UPMC (UMR
7102) Laboratory of Neurobiology of Adaptive Processes, Jean Mariani is an
expert in neurobiology, central nervous system and pathologies, and
neurodegenerative illnesses. He is also Emeritus Professor (PU- PH) at the
Sorbonne University's School of Medicine, and Member of the Board and the
Executive Committee of Gerond'IF.

Stanislas Veillet, President and CEO of Biophytis, said: "I am delighted to
welcome Claude Allary and Benoît Canolle to Biophytis as respectively one of
our new Board members and our new Chief Business Officer.
With great Biotech & Pharma experience & gravitas, Claude will be strongly
contributive to the Board tasks linked to Biophytis next strategic
milestones.
Benoît brings an exceptional background in both R&D and business development
and will be instrumental in valuing the Company's assets going forward.
I would like to thank Jean Mariani for having accepted to take over the Chief
Medical Officer's responsibilities during a transition period, before our new
CMO actually joins the Company".

The Executive Team and myself are looking forward to working closely together
with Claude, Benoît and Jean as well as and with the Board of Directors. We
are strongly committed to advance Sarconeos (BIO101) through very important
clinical milestones for the COVID-19 and sarcopenia studies, from which we
expect results in the coming months."

About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of therapeutics that are aimed at slowing the degenerative
processes associated with aging and improving functional outcomes for patients
suffering from age-related diseases, including severe respiratory failure in
patients suffering from COVID-19.
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, being developed as a treatment for sarcopenia in a Phase 2
clinical trial in the United States and Europe (SARA-INT). It is also being
studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of
severe respiratory manifestations of COVID-19 in Europe, Latin America, and the
US. A pediatric formulation of Sarconeos (BIO101) is being developed for the
treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris,
France, and Cambridge, Massachusetts. The company's common shares are listed on
Euronext Growth (Ticker: ALBPS - ISIN: FR0012816825) and ADSs are listed on
Nasdaq Capital Market (Ticker BPTS - ISIN: US09076G1040). For more information
visit www.biophytis.com

Disclaimer
This press release contains forward-looking statements. Forward-looking
statements include all statements that are not historical facts. In some cases,
you can identify these forward-looking statements by the use of words such as
"outlook," "believes," "expects," "potential," "continues," "may," "will,"
"should," "could," "seeks," "predicts," "intends," "trends," "plans,"
"estimates," "anticipates" or the negative version of these words or other
comparable words. These forward-looking statements include statements regarding
Biophytis' anticipated timing for its various Sarconeos (BIO101) clinical
trials and expectations regarding commercialization. Such forward-looking
statements are based on assumptions that Biophytis considers to be reasonable.
However, there can be no assurance that the statements contained in such
forward-looking statements will be verified, which are subject to various risks
and uncertainties including, without limitation, delays in patient recruitment
or retention, interruptions in sourcing or supply chain, its ability to obtain
the necessary regulatory authorizations, COVID- 19-related delays, and the
impact of the current pandemic on the Company's clinical trials. The
forward-looking statements contained in this press release are also subject to
risks not yet known to Biophytis or not currently considered material by
Biophytis. Accordingly, there are or will be important factors that could cause
actual outcomes or results to differ materially from those indicated in these
statements. Please refer to the "Risk Factors" section of the Company's Annual
2020 Report available on BIOPHYTIS website (www.biophytis.com) and to the risks
discussed in the Company's registration statement on Form F-1 and other reports
filed with the Securities and Exchange Commission (the "SEC"). We undertake no
obligation to publicly update or review any forward-looking statement, whether
as a result of new information, future developments or otherwise, except as
required by law.

Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
evelyne.nguyen@biophytis.com

Media contact
Life Sci Advisors
Sophie Baumont/Chris Maggos
E: sophie@lifesciadvisors.com
T: +33 6 27 74 74 49

Investor Relations
LifeSci Advisors, LLC
Ligia Vela-Reid
E: lvela-reid@lifesciadvisors.com

BIOPHYTIS's latest news

19/04/2024 07:00

BIOPHYTIS (EPA:ALBPS) - Biophytis Reinforces Leadership Teams with Three Senior Appointments

Transparency directive : regulatory news

BIOPHYTIS's latest news

Other stories